CN113677807A - 先兆子痫特异性的循环rna标记 - Google Patents

先兆子痫特异性的循环rna标记 Download PDF

Info

Publication number
CN113677807A
CN113677807A CN202080026261.4A CN202080026261A CN113677807A CN 113677807 A CN113677807 A CN 113677807A CN 202080026261 A CN202080026261 A CN 202080026261A CN 113677807 A CN113677807 A CN 113677807A
Authority
CN
China
Prior art keywords
twenty
rna
thirty
forty
eleven
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080026261.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·E·舒尔扎贝格
F·卡佩尔
S·金宁斯
S·罗尔贝克
C·兰迪斯-辛奇利夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inmair Ltd
Illumina Inc
Original Assignee
Inmair Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmair Ltd filed Critical Inmair Ltd
Publication of CN113677807A publication Critical patent/CN113677807A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080026261.4A 2019-11-22 2020-11-20 先兆子痫特异性的循环rna标记 Pending CN113677807A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939324P 2019-11-22 2019-11-22
US62/939324 2019-11-22
PCT/US2020/061466 WO2021102236A1 (en) 2019-11-22 2020-11-20 Circulating rna signatures specific to preeclampsia

Publications (1)

Publication Number Publication Date
CN113677807A true CN113677807A (zh) 2021-11-19

Family

ID=73835822

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080026261.4A Pending CN113677807A (zh) 2019-11-22 2020-11-20 先兆子痫特异性的循环rna标记

Country Status (7)

Country Link
US (3) US11753685B2 (https=)
EP (1) EP4010495A1 (https=)
JP (1) JP7797199B2 (https=)
CN (1) CN113677807A (https=)
AU (1) AU2020387423A1 (https=)
CA (1) CA3131748A1 (https=)
WO (1) WO2021102236A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024124587A1 (zh) * 2022-12-16 2024-06-20 深圳华大基因股份有限公司 子痫前期生物标志物及其用途
CN119068988A (zh) * 2024-08-13 2024-12-03 北京国浩宇医疗科技有限公司 一种针对单细胞表达谱的智能化异常检测系统

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019227015A1 (en) 2018-05-25 2019-11-28 Illumina, Inc. Circulating rna signatures specific to preeclampsia
US11753685B2 (en) 2019-11-22 2023-09-12 Illumina, Inc. Circulating RNA signatures specific to preeclampsia
US20230394492A1 (en) * 2022-06-02 2023-12-07 Noodle Analytics, Inc. Ai-based defect diagnosis system and method
EP4532769A2 (en) 2022-06-03 2025-04-09 Illumina, Inc. Circulating rna biomarkers for preeclampsia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1991006678A1 (en) 1989-10-26 1991-05-16 Sri International Dna sequencing
ATE377093T1 (de) 2000-07-07 2007-11-15 Visigen Biotechnologies Inc Sequenzbestimmung in echtzeit
AU2002227156A1 (en) 2000-12-01 2002-06-11 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
WO2004018497A2 (en) 2002-08-23 2004-03-04 Solexa Limited Modified nucleotides for polynucleotide sequencing
WO2004065629A1 (en) * 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
DE102004035479A1 (de) 2004-07-14 2006-02-16 Volkswagen Ag Sicherheitssystem für einen Fahrzeugsitz
CA2579150C (en) 2004-09-17 2014-11-25 Pacific Biosciences Of California, Inc. Apparatus and method for analysis of molecules
CA3007182A1 (en) 2005-03-18 2006-09-21 The Chinese University Of Hong Kong Markers for prenatal diagnosis, monitoring or predicting preeclampsia
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
CA2648149A1 (en) 2006-03-31 2007-11-01 Solexa, Inc. Systems and devices for sequence by synthesis analysis
US8343746B2 (en) 2006-10-23 2013-01-01 Pacific Biosciences Of California, Inc. Polymerase enzymes and reagents for enhanced nucleic acid sequencing
EP2132343B1 (en) 2007-03-01 2012-08-29 Université Catholique de Louvain Method for the determination and the classification of rheumatic conditions
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
EP2234483A4 (en) * 2008-01-27 2011-04-27 Rosetta Genomics Ltd METHOD AND COMPOSITIONS FOR DIAGNOSIS OF PREGNANCY COMPLICATIONS
WO2010033553A2 (en) 2008-09-16 2010-03-25 University Of Florida Research Foundation Inc. Gene expression related to preeclampsia
EP2370599B1 (en) 2010-01-19 2015-01-21 Verinata Health, Inc Method for determining copy number variations
US20120270739A1 (en) 2010-01-19 2012-10-25 Verinata Health, Inc. Method for sample analysis of aneuploidies in maternal samples
AU2012276702B2 (en) 2011-06-29 2017-02-09 Toray Industries, Inc. Membrane filtration method and membrane filtration device
US20160289762A1 (en) 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
WO2014132244A1 (en) 2013-02-28 2014-09-04 The Chinese University Of Hong Kong Maternal plasma transcriptome analysis by massively parallel rna sequencing
BR112017007962A2 (pt) 2014-10-24 2018-01-23 Koninklijke Philips Nv método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
US20170234874A1 (en) 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
US11753685B2 (en) 2019-11-22 2023-09-12 Illumina, Inc. Circulating RNA signatures specific to preeclampsia
CN111750067A (zh) 2020-07-07 2020-10-09 精进电动科技股份有限公司 一种用于双动力源驱动减速器的差速锁及驻车结构
EP4532769A2 (en) 2022-06-03 2025-04-09 Illumina, Inc. Circulating rna biomarkers for preeclampsia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTONIO FARINA 等: "Quantitative distribution of a panel of circulating mRNA in preeclampsia versus controls", PRENATAL DIAGNOSIS, 4 September 2006 (2006-09-04), pages 1115 - 1120 *
MICHAEL C.J. QUINN等: "Reprogramming of the Transcriptome in a Novel Chromosome 3 Transfer Tumor Suppressor Ovarian Cancer Cell Line Model Affected Molecular Networks That Are haracteristic of Ovarian Cancer", MOLECULAR CARCINOGENESIS, vol. 48, no. 7, 2 January 2009 (2009-01-02), pages 650 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024124587A1 (zh) * 2022-12-16 2024-06-20 深圳华大基因股份有限公司 子痫前期生物标志物及其用途
CN119068988A (zh) * 2024-08-13 2024-12-03 北京国浩宇医疗科技有限公司 一种针对单细胞表达谱的智能化异常检测系统

Also Published As

Publication number Publication date
AU2020387423A1 (en) 2021-09-30
US11753685B2 (en) 2023-09-12
US20250270646A1 (en) 2025-08-28
US20230135486A1 (en) 2023-05-04
JP7797199B2 (ja) 2026-01-13
JP2023501760A (ja) 2023-01-19
US20210155987A1 (en) 2021-05-27
WO2021102236A1 (en) 2021-05-27
US12359256B2 (en) 2025-07-15
EP4010495A1 (en) 2022-06-15
CA3131748A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
JP7678837B2 (ja) 妊娠高血圧腎症に特異的な循環ｒｎａシグネチャー
US20260055464A1 (en) Methods for profiling and quantitating cell-free rna
CN113677807A (zh) 先兆子痫特异性的循环rna标记
US20230392207A1 (en) Circulating rna biomarkers for preeclampsia
HK40062225A (en) Circulating rna signatures specific to preeclampsia
HK40015099A (en) Circulating rna signatures specific to preeclampsia
US20250361562A1 (en) Cell-free dna signals as biomarkers of preeclampsia
HK40015099B (zh) 对先兆子痫具有特异性的循环rna标识
HK40050272A (en) Circulating rna signatures specific to preeclampsia
HK40050272B (en) Circulating rna signatures specific to preeclampsia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062225

Country of ref document: HK